# CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

> **NCT00038766** · PHASE2 · TERMINATED · sponsor: **Ferring Pharmaceuticals** · enrollment: 33 (actual)

## Conditions studied

- Crohn Disease

## Interventions

- **DRUG:** semapimod
- **DRUG:** semapimod
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00038766
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-06
- **Primary completion:** 2003-06
- **Final completion:** 2003-06
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Unable to enroll into study.
- **Last updated:** 2012-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00038766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00038766, "CNI-1493 for Treatment of Moderate to Severe Crohn's Disease". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00038766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*